Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.40 |
| ▸ | HTR2C | P28335 | 7/20 | 0.40 |
| ▸ | HTR2B | P41595 | 7/20 | 0.40 |
| ▸ | ACHE | P22303 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | BPTF | Q12830 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11559686 | 0.78 | ACHE (0.44) | HTR2AHTR2CHTR2BACHEMEN1 | |
| SCHEMBL2271668 | 0.78 | PDE10A (0.42) | HTR2AHTR2CHTR2BACHEMEN1 | |
| SCHEMBL15661120 | 0.73 | — | — | |
| SCHEMBL30095835 | 0.72 | PDE10A (0.48) | HTR2AHTR2CHTR2BACHEMEN1 | |
| SCHEMBL30095928 | 0.72 | PDE10A (0.48) | HTR2AHTR2CHTR2BACHEMEN1 | |
| SCHEMBL1821069 | 0.71 | ACHE (0.43) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL30350953 | 0.71 | ACHE (0.43) | ACHEMEN1MAPK1KMT2ABPTF | |
| SCHEMBL24699398 | 0.70 | HTR2A (0.53) | HTR2AHTR2CHTR2BACHEPOLB | |
| SCHEMBL15660470 | 0.70 | PDE4B (0.30) | — | |
| SCHEMBL2269295 | 0.70 | HRH4 (0.35) | ACHEMEN1MAPK1KMT2ABPTF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989463-B2 | Biccyclic compounds as GATA modulators | DR. REDDY'S LABORATORIES LIMITED (IN) | 2011-08-02 | — | — | US | disclosed |
| US-7989463-B2 | Biccyclic compounds as GATA modulators | DR. REDDY'S LABORATORIES LIMITED (IN) | 2011-08-02 | — | — | US | disclosed |
| US-7989463-B2 | Biccyclic compounds as GATA modulators | DR. REDDY'S LABORATORIES LIMITED (IN) | 2011-08-02 | — | — | US | disclosed |
| US-20100144731-A1 | Novel Biccyclic Compounds As GATA Modulators | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| US-20100144731-A1 | Novel Biccyclic Compounds As GATA Modulators | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| US-20100144731-A1 | Novel Biccyclic Compounds As GATA Modulators | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| WO-2010028174-A1 | NOVEL BICCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144731-A1 | Novel Biccyclic Compounds As GATA Modulators | GATAD2A, GATAD2B, RUNX1 | HTR2A 2277/4885HTR2C 1461/4885HTR2B 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.